Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEHD7945A versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck after platinum failure
2011-005539-22Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing MEHD7945A with Cetuximab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2012; status: completed.
02
Drugs
duligotuzumabcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-005539-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005539-22.